State Legislation Addressing Specialty Pharmacy Policy

Payer/pharmacy benefit manager (PBM) intrusion into the patient care continuum is a major risk to quality. Treatment delays as a result of white-bagging policies are increasing in frequency. PBM/payer restrictions have increased and are a potential threat to high-quality guideline concordant care as they could steer patients to less efficacious treatments that cost the health plans less money. As the federal government has been slow to act, having an understanding for how state legislatures have begun to address these issues can help those involved in the care of patients with cancer to work within their cancer community to best address these issues at a local level.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe the role of pharmacy benefit managers in the specialty pharmacy process.
  • Discuss how some states are addressing specialty pharmacy policy.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Abbott Molecular
  • Astellas and Seagen Inc.
  • AstraZeneca
  • BeiGene
  • Coherus BioSciences
  • Daiichi Sankyo
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Genmab, US Inc.
  • Gilead Sciences, Inc. and Kite, A Gilead Company
  • GlaxoSmithKline
  • GRAIL, LLC
  • Kadmon Corporation, LLC.
  • Lantheus Medical Imaging Inc.
  • Lilly
  • Menarini-Stemline
  • Novartis
  • NOVOCURE
  • Olympus Corporation of the Americas
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Puma Biotechnology
  • SpringWorks
  • Taiho Oncology, Inc.

This activity is supported by an independent educational grant from:

  • AbbVie
  • Bristol Myers Squibb
  • Incyte
  • Merck & Co., Inc.

This activity is supported by educational funding provided by Amgen.

This activity has been supported by an unrestricted educational grant from GE Healthcare, Pharmaceutical Diagnostics.

This educational activity is supported by an independent medical education grant from Illumina, Inc.

This educational activity is supported by a medical education grant from Karyopharm Therapeutics.

This project has been made possible in part by a grant from Varian Medical Systems, a Siemens Healthineers company/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
06/01/2022
Course expires: 
03/01/2023
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2022 Annual Conference

Michael Kolodziej, MD
ADVI

Kenneth M. Komorny, PharmD, BCPS
Moffitt Cancer Center

Kathy W. Oubre, MS
Pontchartrain Cancer Center

Michael I. Rabin, MBA, MPA
City of Hope National Medical Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Michael I. Rabin, MBA, MPA

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Michael Kolodziej, MD
ADVI: Scientific Advisor; Consulting Fee
Canopy: Equity Interest/Stock Options
CVS: Equity Interest/Stock Options

Kenneth Komorny, PharmD, BCPS
Novartis Pharmaceuticals Corporation: Equity Interest/Stock Options
Pharmacosmos: Honoraria

Kathy W. Oubre, MS
AbbVie, Inc.: Consulting Fee
Genentech, Inc.: Consulting Fee

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-22-061-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 1, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing